Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Study Phase : Approved
Recipient : Milla Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL
Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
Brand Name : Sodium Acetate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Recipient : Milla Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules
Details : Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline...
Brand Name : Lovaza
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : GSK
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
